Otros idiomas Verrica Pharmaceuticals Inc.

Acciones

VRCA

US92511W1080

Mercado cerrado - Nasdaq Otros sitios de cotización 22:30:01 03/05/2024			Varia. Cinco días.	Varia. 1 de enero.
7,26 ^USD	+7,40 %		+5,68 %	-0,82 %

26/03	Ycanth de Verrica Pharmaceuticals obtiene el estatus de Nueva Entidad Química y el listado en el Libro Naranja	MT
26/03	Verrica Pharmaceuticals anuncia que YCANTH? recibe el estatus de Nueva Entidad Química y la inclusión en el Libro Naranja de la FDA	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Verrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference	02/04
Verrica Pharmaceuticals Announces that YCANTH Receives New Chemical Entity Status and Orange Book Listing from the FDA	27/03
Verrica Pharmaceuticals' Ycanth Gets New Chemical Entity Status, Orange Book Listing	26/03
Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA	26/03
Verrica Pharmaceuticals Announces that YCANTH? Receives New Chemical Entity Status and Orange Book Listing from the FDA	26/03
VERRICA PHARMACEUTICALS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA	09/03
Verrica Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/02
Verrica Pharmaceuticals Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	29/02
Earnings Flash (VRCA) VERRICA PHARMACEUTICALS Reports Q4 Revenue $2M, vs. Street Est of $950,000	29/02
Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results	29/02
Verrica Pharmaceuticals Announces Participation in the TD Cowen 44th Annual Healthcare Conference	27/02
Verrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024	22/02
Verrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024	22/02
VERRICA PHARMACEUTICALS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA	14/02
Verrica Pharmaceuticals Sues Dormer Labs for Promoting Unapproved Cantharidin Drugs in US	05/02
Verrica Pharmaceuticals Files Lawsuit Against Canadian Drug Manufacturer for False Advertising and Unfair Competition	05/02
Verrica Pharmaceuticals Files Lawsuit Against Canadian Drug Manufacturer for False Advertising and Unfair Competition	05/02
Verrica Pharmaceuticals Receives Permanent J-Code for YCANTH from Centers for Medicare and Medicaid Services	30/01
Verrica Pharmaceuticals Receives Permanent J-Code (J7354) for YCANTH™ from Centers for Medicare and Medicaid Services	29/01
Verrica Pharmaceuticals Receives Permanent J-Code for YCANTH from Centers for Medicare and Medicaid Services	29/01

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Verrica Pharmaceuticals Inc.

Acciones

VRCA

US92511W1080

Otros idiomas

Filtros